Experimental cancer treatments

Worldwide Oncolytic Virus Immunotherapy Industry to 2026 - Featuring BioVex, Cell Genesys & Crusade Laboratories Among Others

Retrieved on: 
Friday, October 23, 2020
Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Virotherapy, Transgene SA

DUBLIN, Oct. 23, 2020 /PRNewswire/ -- The "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 23, 2020 /PRNewswire/ -- The "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026 Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Increase in prevalence and mortality rate associated with cancer has always remained a challenge to the modern medicine with respect to the development of more reliable therapies.
  • In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy.
  • The market concerned with the growth of the oncolytic virus therapy is also focused on increasing the research and development sector activities.

Global Oncolytic Virus Immunotherapy Market (2020 to 2026) - Dosage, Price & Clinical Trials Outlook - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 22, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Clinical medicine, Medicine, Virotherapy, Experimental cancer treatments, Articles, Biotechnology, Oncolytic virus, Virus, Reoviridae, Transgene SA, Akseli Hemminki

In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy.

Key Points: 
  • In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy.
  • The overall procedure of the therapy is based on the ability of the oncolytic virus to infect and further lyse the tumor cells by boosting the immune system of the patient.
  • Some of the virus strains that have been tested and proved to be adding to the various applications of the therapy are canine distemper virus, adenovirus, vaccinia virus and reovirus in the preclinical and clinical studies.
  • The market concerned with the growth of the oncolytic virus therapy is also focused on increasing the research and development sector activities.

OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference

Retrieved on: 
Monday, October 19, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Clinical medicine, Health, Experimental cancer treatments, Biotechnology, Animal virology, Chordopoxvirinae, Myxoma virus, Immunotherapy, Oncolytic virus, Virotherapy, Virus

OncoMyx Therapeutics , a privately-held viral immunotherapy company, announced the presentation of preclinical data at the AACR Virtual Special Conference: Tumor Immunology and Immunotherapy taking place October 19 to 20.

Key Points: 
  • OncoMyx Therapeutics , a privately-held viral immunotherapy company, announced the presentation of preclinical data at the AACR Virtual Special Conference: Tumor Immunology and Immunotherapy taking place October 19 to 20.
  • The data are the first to demonstrate preclinical therapeutic activity alone and in combination with immune checkpoint inhibitors of the companys armed myxoma virotherapy in development to improve cancer treatment.
  • Myxomas large genome is ideal for multi-arming to create a unique precision medicine approach to oncolytic viruses.
  • OncoMyx Therapeutics develops viral immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer.

BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

Retrieved on: 
Thursday, October 15, 2020
Gene delivery, Branches of biology, Biology, Molecular biology, Genetic engineering, Oncolytic virus, Vector, Transgene, Experimental cancer treatments, Biotechnology

BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.

Key Points: 
  • BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.
  • The poster will be available in the Virtual Poster Hall November 11-14, 2020, 9:00 a.m. - 5:00 p.m. EST (3:00 - 11:00 p.m. CET).
  • Transgene (Euronext Paris: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

BioInvent and Transgene to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

Retrieved on: 
Thursday, October 15, 2020
Gene delivery, Branches of biology, Biology, Molecular biology, Genetic engineering, Oncolytic virus, Vector, Transgene, Experimental cancer treatments, Biotechnology

BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.

Key Points: 
  • BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.
  • The poster will be available in the Virtual Poster Hall November 11-14, 2020, 9:00 a.m. - 5:00 p.m. EST (3:00 - 11:00 p.m. CET).
  • Transgene (Euronext Paris: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Transgene and BioInvent to Present Data on Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting

Retrieved on: 
Thursday, October 15, 2020
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Gene delivery, Branches of biology, Biology, Molecular biology, Genetic engineering, Oncolytic virus, Vector, Transgene, Experimental cancer treatments, Biotechnology

BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.

Key Points: 
  • BT-001 is an optimized oncolytic virus (OV) being co-developed by BioInvent and Transgene.
  • The poster will be available in the Virtual Poster Hall November 11-14, 2020, 9:00 a.m. - 5:00 p.m. EST (3:00 11:00 p.m. CET).
  • Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 14, 2020
Oncolytic virus, Medicine, Melanoma, CTLA-4, Experimental cancer treatments, NMSC, Clinical medicine, Health

The RP2D was selected as up to 10mL of 106 PFU/mL followed Q2W by multiple doses of 107 PFU/mL.

Key Points: 
  • The RP2D was selected as up to 10mL of 106 PFU/mL followed Q2W by multiple doses of 107 PFU/mL.
  • This data supports the hypothesis that anti-CTLA-4 delivered intra-tumorally through oncolytic virus replication, with accompanying antigen release and presentation, can provide potent anti-tumor effects.
  • Results: As of 24th June 2020, 36 melanoma and 16 NMSC patients had been enrolled with follow up of
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.

Global Oncolytic Virus Immunotherapy Market To Reach US$ 750 Million By 2026 With 500% Absolute Growth

Retrieved on: 
Thursday, October 8, 2020
Clinical medicine, Medicine, Biotechnology, Articles, Experimental cancer treatments, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Virus, Virotherapy, Oncolytic herpes virus

NEW DELHI, Oct. 8, 2020 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Oct. 8, 2020 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Increase in prevalence and mortality rate associated with cancer have always remained a challenge to the modern medicine with respect to the development of more reliable therapies.
  • In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy.
  • Prominent factors like these are estimated to enhance access of the patient population to effective oncolytic virus therapy.
  • Gradual increase in the interest of the researchers towards oncolytic virus therapy will develop the market which will eventually bring complete revolution in terms of applications to the cancer patients.

Global Oncolytic Virus Immunotherapy Market To Reach US$ 750 Million By 2026 With 500% Absolute Growth

Retrieved on: 
Thursday, October 8, 2020
Clinical medicine, Medicine, Biotechnology, Articles, Experimental cancer treatments, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Virus, Virotherapy, Oncolytic herpes virus

NEW DELHI, Oct. 8, 2020 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Oct. 8, 2020 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Increase in prevalence and mortality rate associated with cancer have always remained a challenge to the modern medicine with respect to the development of more reliable therapies.
  • In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy.
  • Prominent factors like these are estimated to enhance access of the patient population to effective oncolytic virus therapy.
  • Gradual increase in the interest of the researchers towards oncolytic virus therapy will develop the market which will eventually bring complete revolution in terms of applications to the cancer patients.

OncoMyx to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

Retrieved on: 
Monday, October 5, 2020
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Experimental cancer treatments, Virotherapy, Virology, Oncolytic virus, Myxoma virus, Clinical medicine, Biotechnology, Microbiology, the Chardan Virtual 4th Annual Genetic Medicines Conference, OncoMyx Therapeutics

OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced that members of its senior management team will provide a company update today at 2:30 pm ET and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference.

Key Points: 
  • OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced that members of its senior management team will provide a company update today at 2:30 pm ET and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference.
  • OncoMyx was founded on breakthrough research demonstrating the myxoma virus is highly immuno-interactive and can selectively infect and kill a broad range of cancer cell types.
  • The conference will have presentations from more than 70 public and private companies who are leading the way in the genetic medicines space.
  • OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer.